A Phase IB Study of LXH254 in Combination with Other Drugs in People with Advanced KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer


Full Title

Protocol CLXH254X2102:A Phase Ib, Open-label, Multicenter Study of Oral LXH254-centric Combinations in Adult Patients with Advanced or Metastatic KRAS or BRAF Mutant Non-Small Cell Lung Cancer or NRAS Mutant Melanoma


The purpose of this study is to see if the investigational drug LXH254 given in combination with either LTT462 or trametinib is an effective and safe treatment for people with advanced or metastatic non-small cell lung cancer (NSCLC) that has a BRAF or KRAS gene mutation. Researchers think that treatment with LXH254 in combination with LTT462 or trametinib may help these patients because it can slow down the way by which certain types of BRAF and KRAS mutations cause cancers to grow. All of the drugs used in this study are taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have advanced or metastatic NSCLC with specific BRAF or KRAS gene mutations and which has continued to grow or came back despite standard treatments.
  • At least 4 weeks must pass between the completion of prior therapy and receipt of the study treatment.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Michael Offin at 646-608-3763.